NEKTAR THERAPEUTICS — Director's Dealing 2022

Sep 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2022-09-16

Reporting Person: CHESS ROBERT (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-16	Common Stock	A	10200	$0.00	Acquired	233279	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-16	Stock Option	$3.47	A	20400	Acquired	2030-09-15	Common Stock (20400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2100	Indirect
Common Stock	2100	Indirect
Common Stock	2100	Indirect
Common Stock	28794	Indirect
Common Stock	28000	Indirect

Footnotes

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 16, 2022.

F3: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

F4: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.